The €5m ($5.6m) project has seen 3P Biopharmaceuticals expand its good manufacturing practice (GMP) bacteria area, and install a 50L single-use bioreactor for mammalian cell culture within the facility.
“This provides an attractive option for small batch manufacture as well as for intermediate cell expansion,” according to the firm.
The Spanish Agency of Medicines and Medical Devices has GMP-certified the new facilities.
3P has also adopted Sartorius Stedim Biotech’s ambr 250, a single-use multi-parallel bioreactor, which it said enables the development of 24 different experiments concurrently: “This capacity facilitates rapid decision-making for future manufacturing processes.”
“Furthermore, this technology strengthens the capacity of 3P to carry our process characterisation activities – an essential phase to drive the drug to market,” the firm added.
The contract development and manufacturing organisation (CDMO) has hired more than 50 staff members this year, and expects the business to expand to at least 245 by the end of 2019.